STELARA 130 MG (5MG/ML) VIAL

Pharmacology Ustekinumab is a human monoclonal antibody that binds to and interferes with the proinflammatory cytokines interleukin (IL)-12 and IL-23. Biological effects of IL-12 and IL-23 include natural killer (NK) cell activation CD4+ T-cell differentiation and activation. Ustekinumab also interferes with the expression of monocyte chemotactic protein-1 (MCP-1) tumor necrosis factor-alpha (TNF-a) interferon-inducible protein-10 (IP-10) and interleukin-8 (IL-8). Significant clinical improvement in psoriasis and psoriatic arthritis patients is seen in association with reduction of these proinflammatory signalers. Indications -Crohn disease: Treatment of moderately to severely active Crohn disease in adults who have failed or were intolerant to immunomodulatory or corticosteroid therapy but never failed tumor necrosis factor (TNF) blocker therapy or who have failed or were intolerant to treatment with one or more TNF blockers. -Plaque psoriasis. -Psoriatic arthritis.